Risk factors predictive of joint replacement in a 2-year multicentre clinical trial in knee osteoarthritis using MRI: Results from over 6 years of observation

Annals of the Rheumatic Diseases

Volumn 70, Issue 8, 2011, Pages 1382-1388

  Raynauld, Jean Pierre ^a   Martel Pelletier, Johanne ^a   Haraoui, Boulos ^a   Choquette, Denis ^a   Dorais, Marc ^b   Wildi, Lukas M ^a   Abram, François ^c   Pelletier, Jean Pierre ^a  

^a NOTRE DAME HOSPITAL   (Canada)

^b StatSciences Inc   (Canada)

^c INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; LICOFELONE; NAPROXEN;

ADULT; ARTICLE; BONE MARROW DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; INCIDENCE; INTERVIEW; JOINT CAVITY; KNEE MENISCUS RUPTURE; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; TELEPHONE; TOTAL KNEE REPLACEMENT;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHROPLASTY, REPLACEMENT, KNEE; C-REACTIVE PROTEIN; DISEASE PROGRESSION; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; KNEE JOINT; MAGNETIC RESONANCE IMAGING; MALE; MENISCI, TIBIAL; MIDDLE AGED; NAPROXEN; OSTEOARTHRITIS, KNEE; PROGNOSIS; PYRROLES;

EID: 79959846767     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.146407     Document Type: Article

References (45)

1. Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145-55.
2. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthr Cartil 2007;15:981-1000. (Pubitemid 47393443)
3. Brandt KD, Mazzuca SA, Conrozier T, et al. Which is the best radiographic protocol for a clinical trial of a structure modifying drug in patients with knee osteoarthritis? J Rheumatol 2002;29:1308-20. (Pubitemid 34601970)
4. Dougados M, Nguyen M, Berdah L, et al. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the Chondromodulating Effect of Diacerein in OA of the Hip. Arthritis Rheum 2001;44:2539-47. (Pubitemid 33049332)
5. Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001;357:251-6. (Pubitemid 32120855)
6. Pavelká K, Gatterová J, Olejarová M, et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, doubleblind study. Arch Intern Med 2002;162:2113-23. (Pubitemid 35168220)
7. Michel BA, Stucki G, Frey D, et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum 2005;52:779-86. (Pubitemid 40365099)
8. Kahan A, Uebelhart D, De Vathaire F, et al. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009; 60:524-33.
9. Cicuttini FM, Wluka AE, Stuckey SL. Tibial and femoral cartilage changes in knee osteoarthritis. Ann Rheum Dis 2001;60:977-80. (Pubitemid 32885675)
10. Biswal S, Hastie T, Andriacchi TP, et al. Risk factors for progressive cartilage loss in the knee: a longitudinal magnetic resonance imaging study in forty-three patients. Arthritis Rheum 2002;46:2884-92. (Pubitemid 35315879)
11. Felson DT, McLaughlin S, Goggins J, et al. Bone marrow edema and its relation to progression of knee osteoarthritis. Ann Intern Med 2003;139:330-6.
12. Raynauld JP, Martel-Pelletier J, Berthiaume MJ, et al. Quantitative magnetic resonance imaging evaluation of knee osteoarthritis progression over two years and correlation with clinical symptoms and radiologic changes. Arthritis Rheum 2004; 50:476-87. (Pubitemid 38198832)
13. Hayes CW, Jamadar DA, Welch GW, et al. Osteoarthritis of the knee: comparison of MR imaging findings with radiographic severity measurements and pain in middle-aged women. Radiology 2005;237:998-1007. (Pubitemid 41636393)
14. Hunter DJ, Zhang Y, Niu J, et al. Increase in bone marrow lesions associated with cartilage loss: a longitudinal magnetic resonance imaging study of knee osteoarthritis. Arthritis Rheum 2006;54:1529-35.
15. Pelletier JP, Raynauld JP, Caron J, et al. Decrease in serum level of matrix metalloproteinases is predictive of the disease-modifying effect of osteoarthritis drugs assessed by quantitative MRI in patients with knee osteoarthritis. Ann Rheum Dis 2010;69:2095-101.
16. Berthiaume MJ, Raynauld JP, Martel-Pelletier J, et al. Meniscal tear and extrusion are strongly associated with progression of symptomatic knee osteoarthritis as assessed by quantitative magnetic resonance imaging. Ann Rheum Dis 2005; 64:556-63. (Pubitemid 40469084)
17. Mazzuca SA, Brandt KD, Katz BP, et al. Risk factors for early radiographic changes of tibiofemoral osteoarthritis. Ann Rheum Dis 2007;66:394-9. (Pubitemid 46579643)
18. Raynauld JP, Martel-Pelletier J, Bias P, et al. Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI. Ann Rheum Dis 2009;68:938-47.
19. Raynauld JP, Martel-Pelletier J, Beaulieu A, et al. An open-label pilot study evaluating by magnetic resonance imaging the potential for a disease-modifying effect of celecoxib compared to a modelized historical control cohort in the treatment of knee osteoarthritis. Semin Arthritis Rheum 2010;40:185-92.
20. US Department of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health. Guidance for the Industry. Clinical Development Programs for Drugs, Devices and Biological Products Intended for the Treatment Osteoarthritis. Draft, July 1999; Food and Drug Administration, Rockville, MD, USA.
21. Committee for Medicinal Products for Human Use (CHMP). Guideline on Clinical Investigation of Medicinal Products Used in the Treatment of Osteoarthritis (CPMP/ EWP/784/97 Rev 1). London: European Medicines Agency, January 2010.
22. Altman RD, Abadie E, Avouac B, et al. Total joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis. Osteoarthr Cartil 2005;13:13-19. (Pubitemid 40104258)
23. Wang Y, Simpson JA, Wluka AE, et al. Relationship between body adiposity measures and risk of primary knee and hip replacement for osteoarthritis: a prospective cohort study. Arthritis Res Ther 2009;11:R31.
24. Wang Y, Simpson JA, Wluka AE, et al. Reduced rates of primary joint replacement for osteoarthritis in Italian and Greek migrants to Australia: the Melbourne Collaborative Cohort Study. Arthritis Res Ther 2009;11:R86.
25. Tanamas SK, Wluka AE, Pelletier JP, et al. Bone marrow lesions in people with knee osteoarthritis predict progression of disease and joint replacement: a longitudinal study. Rheumatology (Oxford) 2010;49:2413-19.
26. Tanamas SK, Wluka AE, Pelletier JP, et al. The association between subchondral bone cysts and tibial cartilage volume and risk of joint replacement in people with knee osteoarthritis: a longitudinal study. Arthritis Res Ther 2010;12:R58.
27. Bruyere O, Pavelka K, Rovati LC, et al. Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthr Cartil 2008;16:254-60. (Pubitemid 351218188)
28. Raynauld JP, Kauffmann C, Beaudoin G, et al. Reliability of a quantification imaging system using magnetic resonance images to measure cartilage thickness and volume in human normal and osteoarthritic knees. Osteoarthr Cartil 2003;11:351-60. (Pubitemid 36621845)
29. Eckstein F, Cicuttini F, Raynauld JP, et al. Magnetic resonance imaging (MRI) of articular cartilage in knee osteoarthritis (OA): morphological assessment. Osteoarthr Cartil 2006;14 (Suppl A): A46-75.
30. Kauffmann C, Gravel P, Godbout B, et al. Computer-aided method for quantification of cartilage thickness and volume changes using MRI: validation study using a synthetic model. IEEE Trans Biomed Eng 2003;50:978-88.
31. Raynauld JP, Martel-Pelletier J, Berthiaume MJ, et al. Long term evaluation of disease progression through the quantitative magnetic resonance imaging of symptomatic knee osteoarthritis patients: correlation with clinical symptoms and radiographic changes. Arthritis Res Ther 2006;8:R21.
32. Vignon E, Piperno M, Le Graverand MP, et al. Measurement of radiographic joint space width in the tibiofemoral compartment of the osteoarthritic knee: comparison of standing anteroposterior and Lyon Schuss views. Arthritis Rheum 2003;48:378-84. (Pubitemid 36278005)
33. Bellamy N, Buchanan WW, Goldsmith CH, et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-40. (Pubitemid 19037656)
34. Cicuttini FM, Jones G, Forbes A, et al. Rate of cartilage loss at two years predicts subsequent total knee arthroplasty: a prospective study. Ann Rheum Dis 2004;63:1124-7. (Pubitemid 39120365)
35. Bruyere O, Richy F, Reginster JY. Three year joint space narrowing predicts long term incidence of knee surgery in patients with osteoarthritis: an eight year prospective follow up study. Ann Rheum Dis 2005;64:1727-30. (Pubitemid 41667146)
36. Jovanovic DV, Fernandes JC, Martel-Pelletier J, et al. In vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis: suppression of collagenase 1 and interleukin-1beta synthesis. Arthritis Rheum 2001;44:2320-30. (Pubitemid 32977499)
37. Pelletier JP, Boileau C, Boily M, et al. The protective effect of licofelone on experimental osteoarthritis is correlated with the downregulation of gene expression and protein synthesis of several major cartilage catabolic factors: MMP-13, cathepsin K and aggrecanases. Arthritis Res Ther 2005;7:R1091-102.
38. Brandt KD, Mazzuca SA, Katz BP, et al. Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum 2005;52:2015-25. (Pubitemid 40994324)
39. Gossec L, Jordan JM, Mazzuca SA, et al. Comparative evaluation of three semi-quantitative radiographic grading techniques for knee osteoarthritis in terms of validity and reproducibility in 1759 X-rays: report of the OARSI-OMERACT task force. Osteoarthr Cartil 2008;16:742-8.
40. Wluka AE, Wolfe R, Stuckey S, et al. How does tibial cartilage volume relate to symptoms in subjects with knee osteoarthritis? Ann Rheum Dis 2004;63:264-8. (Pubitemid 38250668)
41. Felson DT, Niu J, Guermazi A, et al. Correlation of the development of knee pain with enlarging bone marrow lesions on magnetic resonance imaging. Arthritis Rheum 2007;56:2986-92. (Pubitemid 47502745)
42. Yusuf E, Kortekaas MC, Watt I, et al. Do knee abnormalities visualised on MRI explain knee pain in knee osteoarthritis? A systematic review. Ann Rheum Dis 2011;70:60-7.
43. Raynauld JP, Martel-Pelletier J, Berthiaume MJ, et al. Correlation between bone lesion changes and cartilage volume loss in patients with osteoarthritis of the knee as assessed by quantitative magnetic resonance imaging over a 24-month period. Ann Rheum Dis 2008;67:683-8. (Pubitemid 351571934)
44. d'Anjou MA, Troncy E, Moreau M, et al. Response to the Letter to the Editor by Roemer and collaborators entitled "MRI based semi-quantitative assessment of subchondral bone marrow lesions in osteoarthritis research" concerning the article published by d'Anjou et al entitled "Temporal assessment of bone marrow lesions on magnetic resonance imaging in a canine model of knee osteoarthritis: impact of sequence selection." Osteoarthr Cartil 2009;17:416-17.
45. Bingham CO III, Buckland-Wright JC, Garnero P, et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 2006;54:3494-507. (Pubitemid 44737161)